Roche presents encouraging new data in common blood cancers for its investigational BCL-2 inhibitor GDC-0199/ABT-199 and polatuzumab vedotin, an anti-CD79b antibody drug conjugate

GDC-0199/ABT-199 combined with rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) shows encouraging activity. Head-to-head ROMULUS data in R/R non-Hodgkin lymphoma (NHL) support further development of polatuzumab vedotin (anti-CD79b ADC).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news